INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 43m ago
HOUSE PTR2m ago
SEC 13F2m ago
ROBINHOOD CHAIN2m ago
Corporate insider
WC

Walsh Colin

DirectorCIK 0001866174

EDGAR filingsOpen in network
Disclosed transactions29
Buys / sells2 / 23
Max Insider Score60
Connections1with evidence

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
31
WC
Walsh ColinDirector
ATTOAttovia Therapeutics, Inc.
Open-market sale
SELL$8,808
400 sh
Aug 5, 2026Aug 13, 2026
traded Aug 5, 2026
+8dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    Attovia Therapeutics, Inc.Director · Aug 13, 2026
31
WC
Walsh ColinDirector
ATTOAttovia Therapeutics, Inc.
Open-market sale
SELL
$26K
1,163 sh
Aug 5, 2026
Aug 13, 2026
traded Aug 5, 2026
+8d
SEC FORM 4

Evidence

41
WC
Walsh ColinDirector
ATTOAttovia Therapeutics, Inc.
Open-market purchase
BUY$8.50M
500.0K sh
Aug 6, 2026Aug 13, 2026
traded Aug 6, 2026
+7dSEC FORM 4

Evidence

31
WC
Walsh ColinDirector
ATTOAttovia Therapeutics, Inc.
Open-market sale
SELL$10K
480 sh
Aug 5, 2026Aug 13, 2026
traded Aug 5, 2026
+8dSEC FORM 4

Evidence

8
WC
Walsh ColinDirector
ATTOAttovia Therapeutics, Inc.
Derivative conversion
C—
18.18M sh
Aug 6, 2026Aug 13, 2026
traded Aug 6, 2026
+7dSEC FORM 4

Evidence

8
WC
Walsh ColinDirector
ATTOAttovia Therapeutics, Inc.
Derivative conversion
C—
4.45M sh
Aug 6, 2026Aug 13, 2026
traded Aug 6, 2026
+7dSEC FORM 4

Evidence

31
WC
Walsh ColinDirector
ATTOAttovia Therapeutics, Inc.
Open-market sale
SELL$2,211
100 sh
Aug 5, 2026Aug 13, 2026
traded Aug 5, 2026
+8dSEC FORM 4

Evidence

31
WC
Walsh ColinDirector
ATTOAttovia Therapeutics, Inc.
Open-market sale
SELL$4,410
200 sh
Aug 5, 2026Aug 13, 2026
traded Aug 5, 2026
+8dSEC FORM 4

Evidence

31
WC
Walsh ColinDirector
ATTOAttovia Therapeutics, Inc.
Open-market sale
SELL$15K
700 sh
Aug 5, 2026Aug 13, 2026
traded Aug 5, 2026
+8dSEC FORM 4

Evidence

38
WC
Walsh ColinDirector
ATTOAttovia Therapeutics, Inc.
Open-market sale
SELL$146K
6,763 sh
Aug 5, 2026Aug 13, 2026
traded Aug 5, 2026
+8dSEC FORM 4

Evidence

31
WC
Walsh ColinDirector
ATTOAttovia Therapeutics, Inc.
Open-market sale
SELL$6,252
300 sh
Aug 5, 2026Aug 13, 2026
traded Aug 5, 2026
+8dSEC FORM 4

Evidence

52
WC
Walsh ColinDirector
ATTOAttovia Therapeutics, Inc.
Open-market sale
SELL$1.61M
76.4K sh
Aug 5, 2026Aug 13, 2026
traded Aug 5, 2026
+8dSEC FORM 4

Evidence

31
WC
Walsh ColinDirector
ATTOAttovia Therapeutics, Inc.
Open-market sale
SELL$22K
988 sh
Aug 5, 2026Aug 13, 2026
traded Aug 5, 2026
+8dSEC FORM 4

Evidence

31
WC
Walsh ColinDirector
ATTOAttovia Therapeutics, Inc.
Open-market sale
SELL$9,776
447 sh
Aug 5, 2026Aug 13, 2026
traded Aug 5, 2026
+8dSEC FORM 4

Evidence

31
WC
Walsh ColinDirector
ATTOAttovia Therapeutics, Inc.
Open-market sale
SELL$29K
1,332 sh
Aug 5, 2026Aug 13, 2026
traded Aug 5, 2026
+8dSEC FORM 4

Evidence

31
WC
Walsh ColinDirector
ATTOAttovia Therapeutics, Inc.
Open-market sale
SELL$4,410
200 sh
Aug 5, 2026Aug 13, 2026
traded Aug 5, 2026
+8dSEC FORM 4

Evidence

31
WC
Walsh ColinDirector
ATTOAttovia Therapeutics, Inc.
Open-market sale
SELL$34K
1,556 sh
Aug 5, 2026Aug 13, 2026
traded Aug 5, 2026
+8dSEC FORM 4

Evidence

34
WC
Walsh ColinDirector
ATTOAttovia Therapeutics, Inc.
Open-market sale
SELL$75K
3,402 sh
Aug 5, 2026Aug 13, 2026
traded Aug 5, 2026
+8dSEC FORM 4

Evidence

31
WC
Walsh ColinDirector
ATTOAttovia Therapeutics, Inc.
Open-market sale
SELL$4,420
200 sh
Aug 5, 2026Aug 13, 2026
traded Aug 5, 2026
+8dSEC FORM 4

Evidence

31
WC
Walsh ColinDirector
ATTOAttovia Therapeutics, Inc.
Open-market sale
SELL$17K
753 sh
Aug 5, 2026Aug 13, 2026
traded Aug 5, 2026
+8dSEC FORM 4

Evidence

31
WC
Walsh ColinDirector
ATTOAttovia Therapeutics, Inc.
Open-market sale
SELL$15K
672 sh
Aug 5, 2026Aug 13, 2026
traded Aug 5, 2026
+8dSEC FORM 4

Evidence

38
WC
Walsh ColinDirector
ATTOAttovia Therapeutics, Inc.
Open-market sale
SELL$154K
6,970 sh
Aug 5, 2026Aug 13, 2026
traded Aug 5, 2026
+8dSEC FORM 4

Evidence

31
WC
Walsh ColinDirector
ATTOAttovia Therapeutics, Inc.
Open-market sale
SELL$26K
1,180 sh
Aug 5, 2026Aug 13, 2026
traded Aug 5, 2026
+8dSEC FORM 4

Evidence

31
WC
Walsh ColinDirector
ATTOAttovia Therapeutics, Inc.
Open-market sale
SELL$23K
1,040 sh
Aug 5, 2026Aug 13, 2026
traded Aug 5, 2026
+8dSEC FORM 4

Evidence

31
WC
Walsh ColinDirector
ATTOAttovia Therapeutics, Inc.
Open-market sale
SELL$9,649
443 sh
Aug 5, 2026Aug 13, 2026
traded Aug 5, 2026
+8dSEC FORM 4

Evidence

60
WC
Walsh ColinDirector
ATTOAttovia Therapeutics, Inc.
Open-market purchase
BUY$1.78M
85.0K sh
Aug 5, 2026Aug 13, 2026
traded Aug 5, 2026
+8dSEC FORM 4

Evidence

20
WC
Walsh ColinDirector
ATTOAttovia Therapeutics, Inc.
Derivative conversion
C—
1.96M sh
Aug 6, 2026Aug 13, 2026
traded Aug 6, 2026
+7dSEC FORM 4

Evidence

16
WC
Walsh ColinDirector
ATTOAttovia Therapeutics, Inc.
Derivative conversion
C—
478.5K sh
Aug 6, 2026Aug 13, 2026
traded Aug 6, 2026
+7dSEC FORM 4

Evidence

31
WC
Walsh ColinDirector
ATTOAttovia Therapeutics, Inc.
Open-market sale
SELL$2,199
100 sh
Aug 5, 2026Aug 13, 2026
traded Aug 5, 2026
+8dSEC FORM 4

Evidence